Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q15910

UPID:
EZH2_HUMAN

ALTERNATIVE NAMES:
ENX-1; Enhancer of zeste homolog 2; Lysine N-methyltransferase 6

ALTERNATIVE UPACC:
Q15910; B2RAQ1; B3KS30; B7Z1D6; B7Z7L6; Q15755; Q75MG3; Q92857; Q96FI6

BACKGROUND:
The protein Histone-lysine N-methyltransferase EZH2, with alternative names ENX-1 and Enhancer of zeste homolog 2, is a Polycomb group protein integral to the PRC2/EED-EZH2 complex. It catalyzes the methylation of 'Lys-27' on histone H3, leading to gene silencing. EZH2 is essential for embryonic stem cell identity by forming H3K27me3 and plays a significant role in cellular differentiation. Its ability to methylate non-histone proteins like GATA4 and RORA further illustrates its versatile role in gene expression regulation.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Histone-lysine N-methyltransferase EZH2 could open doors to potential therapeutic strategies. Its direct link to Weaver syndrome through gene variants provides a foundation for developing targeted treatments, highlighting the therapeutic significance of EZH2 in addressing genetic and epigenetic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.